Company Intelligence Profile

Morepen Laboratories Limited

Morepen Laboratories is a 40+ year old pharmaceutical manufacturer headquartered/manufacturing out of Baddi, Himachal Pradesh (10 plants).

CIN: L24231HP1984PLC006028Active; ListedRoC Himachal Pradesh [Source: TheCompanyCheck]Confidence: high

Last updated 6 September 2026

AI OverviewGenerated from public records

AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.

See what AICA knows about Morepen Laboratories

Deeper analysis, financial signals and peer comparisons.

Book a demo

Company Identity

Confirmed
Registered nameMorepen Laboratories Limited
CINL24231HP1984PLC006028
PANAABCM1083B
Status
  • Active
  • Listed (NSE: MOREPENLAB, BSE: 500288)
ListingYes — NSE: MOREPENLAB, BSE: 500288
Incorporated01 December 1984
ROCRoC Himachal Pradesh
Sector (NIC)
  • Pharmaceuticals — chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products
  • API (Active Pharmaceutical Ingredient) manufacturer
  • Specific NIC code not obtained
Registered address
  • Village Morepen, Nalagarh Road, Near Baddi, Distt
  • Solan, Himachal Pradesh – 173205, India
Authorized capital₹250 crore
Paid-up capital₹109.6 crore (~₹109.58 Cr)

Business Overview

Confirmed
  • Morepen Laboratories is a 40+ year old pharmaceutical manufacturer headquartered/manufacturing out of Baddi, Himachal Pradesh (10 plants)
  • Business segments: (1) Global Generics — APIs including montelukast (~45MT/yr capacity) and loratadine (90%+ US market share for the molecule)
  • (2) Home Diagnostics — blood glucose monitors, BP monitors, serving 4M+ users
  • (3) Dr. Morepen — 400+ OTC healthcare/consumer products including legacy brand Burnol
  • (4) Finished formulations across generic therapeutic categories
  • Exports to 80+ countries; holds USFDA, WHO-GMP, EU-GMP certifications
  • Recently secured an ₹825 crore CDMO mandate and posted highest-ever quarterly revenue in Q1 FY27

Directors

Confirmed
NameDINRoleAppointed
Sushil Suri00012028Managing Director-
Sanjay Suri00041590Whole-time Director-
Praveen Kumar Dutt06712574Director-
Ranjit Khattar00726997Director-
Sharad Jain06423452Director-

Financials

Confirmed
  • FY26 (year ended March 2026, per Screener.in, standalone/consolidated basis not explicitly labeled — treat as consolidated per Screener convention): Revenue ₹1,681 Cr
  • EBITDA ₹112 Cr
  • PAT ₹66 Cr
  • Net Worth ₹1,243 Cr (Equity Capital ₹110 Cr + Reserves ₹1,133 Cr)
  • Borrowings ₹205 Cr. Q1 FY27 (June 2026): Revenue ₹541 Cr, EBITDA ₹80 Cr, PAT ₹54 Cr, EPS ₹0.99
  • Cross-check via Tofler (FY 2024-25/March 2025 data): Total Revenue ₹1,500-1,750 Cr band, Net Worth ₹1,077.4 Cr, Total Assets ₹1,778.1 Cr, Borrowings ₹79.4 Cr, Debt-to-Equity 0.04 — figures are broadly consistent with revenue growing YoY into FY26, though Tofler's FY25 borrowings figure (₹79.4 Cr) is notably lower than Screener's FY26 figure (₹205 Cr), a real reported increase rather than a conflict

In the News

Confirmed
  • Morepen Laboratories Bags ₹825 Crore Global Deal, Expands Into High-Growth CDMO Segment

    scanx.trade · 16 days ago

  • Morepen Laboratories files FY26 BRSR report, details sustainability metrics

    scanx.trade · 18 days ago

  • Morepen Laboratories sets Sept 26 for 41st AGM; proposes ₹0.20 dividend

    scanx.trade · 18 days ago

  • Morepen Laboratories Ltd. Key Financial Ratios – Valuation, Profitability & More

    Value Research · 21 days ago

  • Morepen Laboratories Share Price today after yearly high

    Univest · 24 days ago

Headlines about Morepen Laboratories Limited reported by third-party publications. Recur Club does not author or endorse this coverage. Last checked 14 days ago.

Source: Google News aggregated headlines

Shareholding

Confirmed
  • As of March 2026 / June 2026 (Screener.in): Promoters ~35.65-35.66%
  • FIIs ~1.46-1.58%
  • DIIs ~1.25-1.28%
  • Public/Retail & Others ~61.50-61.59%
  • Total shareholders ~4.3-4.47 lakh. Promoter holding has ranged 34.54% (Dec 2015) to 38.38% (Mar 2022) historically

Charges/Loans

Partial / conflicting
  • Kotak Mahindra Bank Limited — ₹99.0 Cr (charge dated Jan 20, 2025)
  • Qatar National Bank — ₹50.0 Cr (May 23, 2025)
  • Mercedes-Benz Financial Services — ₹4.8 Cr across 4 loans
  • Kotak Mahindra Prime Limited — ₹4.0 Cr across 12 loans
  • BMW India Financial Services — ₹1.2 Cr

Competitors

Partial / conflicting
Divi's Laboratories
large-cap API/CDMO leader, much larger scale than Morepen
Aarti Drugs
mid-cap API manufacturer, comparable/slightly smaller scale
Ipca Laboratories
larger formulations+API player
Cipla
large-cap, much bigger diversified pharma
Alkem Laboratories
large-cap formulations
Emcure Pharmaceuticals
comparable-to-larger formulations player

Frequently Asked Questions

What does Morepen Laboratories Limited do?
Morepen Laboratories is a 40+ year old pharmaceutical manufacturer headquartered/manufacturing out of Baddi, Himachal Pradesh (10 plants).
What is the CIN of Morepen Laboratories Limited?
The Corporate Identification Number (CIN) of Morepen Laboratories Limited is L24231HP1984PLC006028.
Where is Morepen Laboratories Limited registered?
Morepen Laboratories Limited is registered with RoC Himachal Pradesh [Source: TheCompanyCheck]. Registered address: Village Morepen, Nalagarh Road, Near Baddi, Distt.
When was Morepen Laboratories Limited incorporated?
Morepen Laboratories Limited was incorporated on 01 December 1984 [Source: TheCompanyCheck, Tofler].

Explore on Recur Club

Bharat Ke Super Founders

Recur Club's show spotlighting the founders building India's next generation of companies. Watch their stories.

Watch the show

Looking for business funding?

Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.

Disclaimer: Company information shown on this page is compiled from public records and third-party sources. It may be incomplete, outdated, or contain inaccuracies, and is provided for general informational purposes only. Please verify details independently before relying on them.